Intensivtherapie nach Leber-, Nieren- und Pankreas-Transplantation

In den 40 Transplantationszentren in Deutschland wurden 2021 insgesamt 2979 solide Organe transplantiert. Darunter waren 780 Leber-, 1517 Nieren- und 65 Pankreastransplantationen. Transplantationen sind durch einen erheblichen Ressourcenverbrauch gekennzeichnet und nur an Transplantationszentren möglich. Der Artikel beschäftigt sich mit der Immunsuppression und den speziellen Aspekten der Intensivtherapie nach Leber-, Nieren- bzw. Nieren-Pankreas-Transplantation.

Schlüsselwörter

Intensivtherapie - Lebertransplantation - Nierentransplantation - Pankreastransplantation - Immunsuppression

• Literatur

• 1 Jasiak NM, Park JM. Immunosuppression in Solid-Organ Transplantation: Essentials and Practical Tips. Crit Care Nurs Q 2016; 39: 227-240
• 2 Starzl TE, Weil 3rd R, Iwatsuki S. et al. The use of cyclosporin A and prednisone in cadaver kidney transplantation. Surg Gynecol Obstet 1980; 151: 17-26
• 3 Ekberg H, Tedesco-Silva H, Demirbas A. et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562-2575
• 4 Duvoux C, Toso C. mTOR inhibitor therapy: Does it prevent HCC recurrence after liver transplantation?. Transplant Rev (Orlando) 2015; 29: 168-174
• 5 El-Charabaty E, Geara AS, Ting C. et al. Belatacept: a new era of immunosuppression?. Expert Rev Clin Immunol 2012; 8: 527-536
• 6 Beiras-Fernandez A, Thein E, Hammer C. Induction of immunosuppression with polyclonal antithymocyte globulins: an overview. Exp Clin Transplant 2003; 1: 79-84
• 7 Wagner SJ, Brennan DC. Induction therapy in renal transplant recipients: how convincing is the current evidence?. Drugs 2012; 72: 671-683
• 8 Webster AC, Ruster LP, McGee R. et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev 2010; 2010 (01) CD003897
• 9 Mulley WR, Kanellis J. Understanding crossmatch testing in organ transplantation: A case-based guide for the general nephrologist. Nephrology (Carlton) 2011; 16: 125-133
• 10 Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998; 338: 1741-1751
• 11 Humar A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006; 6: 262-274
• 12 Pescovitz MD, Rabkin J, Merion RM. et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000; 44: 2811-2815
• 13 Cheung CY, Tang SCW. An update on cancer after kidney transplantation. Nephrol Dial Transplant 2019; 34: 914-920
• 14 Acharya G, Kaushik RM, Gupta R. et al. Child-Turcotte-Pugh Score, MELD Score and MELD-Na Score as Predictors of Short-Term Mortality among Patients with End-Stage Liver Disease in Northern India. Inflamm Intest Dis 2020; 5: 1-10
• 15 Ginès P, Solà E, Angeli P. et al. Hepatorenal syndrome. Nat Rev Dis Primers 2018; 4: 23
• 16 Raevens S, Geerts A, Van Steenkiste C. et al. Hepatopulmonary syndrome and portopulmonary hypertension: recent knowledge in pathogenesis and overview of clinical assessment. Liver Int 2015; 35: 1646-1660
• 17 Tatum R, O’Malley TJ, Bodzin AS. et al. Machine perfusion of donor organs for transplantation. Artif Organs 2021; 45: 682-695
• 18 Dobrindt EM, Eurich D, Veltzke-Schlieker W. et al. Ischemic-type biliary lesions after liver transplant: factors causing early-onset versus late-onset disease. Exp Clin Transplant 2020; 18: 591-597
• 19 Grigg SE, Sarri GL, Gow PJ. et al. Systematic review with meta-analysis: sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther 2019; 49: 1260-1273
• 20 Kasiske BL, Zeier MG, Chapman JR. et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int 2010; 77: 299-311